Shosei Ro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shosei Ro has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Torahiko Jinta
Department of Respiratory Medicine, Thoracic Center, St. Luke's International Hospital, Tokyo, Japan
4 shared publications- Atsushi Kitamura
St. Luke's International Hospital, Tokyo, Japan
3 shared publications - Clara So
Department of Pulmonary Medicine, Thoracic Center St. Luke's International Hospital Tokyo Japan
3 shared publications - Kohei Okafuji
Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Tokyo, Japan
3 shared publications - Manabu Murakami
Center for Medical Education and International Relations, Faculty of Medicine, Hokkaido University, Hokkaido, Japan
3 shared publications - Naoki Nishimura
Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
3 shared publications
Latest Publications
- 1 November 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 772-776
Reproducibility of peripheral branches in virtual bronchoscopic navigation using VINCENT and LungPoint software for peripheral lung lesions
- 1 November 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (6) , 772-776
Reproducibility of peripheral branches in virtual bronchoscopic navigation using VINCENT and LungPoint software for peripheral lung lesions
- 1 September 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (5) , 608-613
Steroid resistance and rebound phenomena in patients with COVID-19
- 1 September 2021
- Published by Elsevier in Respiratory Investigation
- Vol. 59 (5) , 608-613
Steroid resistance and rebound phenomena in patients with COVID-19
- Open Access
- 30 June 2021
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 16 (1) , 781
Identification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy
Background: Corticosteroids have been reported to reduce the mortality rates in patients with coronavirus disease 2019 (COVID-19). Additionally, the role of high-dose methylprednisolone pulse therapy in reducing mortality in critically ill patients has also been documented. The purpose of this study is to identify patients with COVID-19 who are suitable for methylprednisolone pulse therapy.Methods: This was a retrospective study that included patients with COVID-19 receiving methylprednisolone pulse therapy (>250 mg/day for 3 days) with subsequent tapering doses at our hospital between June 2020 and January 2021. We examined the differences in background clinical factors between the surviving group and the deceased group.Results: Of 156 patients that received steroid therapy, 17 received methylprednisolone pulse therapy. Ten patients recovered (surviving group) and seven patients died (deceased group). The median age of the surviving and deceased groups was 64.5 years (range, 57-85) and 79 years (73-90), respectively, with a significant difference (p=0.004). Five of the deceased patients (71%) had developed serious complications associated with the cause of death, including pneumothorax, pneumomediastinum, COVID-19-associated pulmonary aspergillosis, cytomegalovirus infection, and bacteremia. On the other hand, of the 10 survivors, only one elderly person had cytomegalovirus infection and the rest recovered without complications.Conclusion: Administration of methylprednisolone pulse therapy with subsequent tapering may be an effective treatment in patients with COVID-19 up to the age of early 70s; however, severe complications may be seen in elderly patients.
- 30 June 2021
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 16 (1) , 781
Open AccessIdentification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy
Background: Corticosteroids have been reported to reduce the mortality rates in patients with coronavirus disease 2019 (COVID-19). Additionally, the role of high-dose methylprednisolone pulse therapy in reducing mortality in critically ill patients has also been documented. The purpose of this study is to identify patients with COVID-19 who are suitable for methylprednisolone pulse therapy.Methods: This was a retrospective study that included patients with COVID-19 receiving methylprednisolone pulse therapy (>250 mg/day for 3 days) with subsequent tapering doses at our hospital between June 2020 and January 2021. We examined the differences in background clinical factors between the surviving group and the deceased group.Results: Of 156 patients that received steroid therapy, 17 received methylprednisolone pulse therapy. Ten patients recovered (surviving group) and seven patients died (deceased group). The median age of the surviving and deceased groups was 64.5 years (range, 57-85) and 79 years (73-90), respectively, with a significant difference (p=0.004). Five of the deceased patients (71%) had developed serious complications associated with the cause of death, including pneumothorax, pneumomediastinum, COVID-19-associated pulmonary aspergillosis, cytomegalovirus infection, and bacteremia. On the other hand, of the 10 survivors, only one elderly person had cytomegalovirus infection and the rest recovered without complications.Conclusion: Administration of methylprednisolone pulse therapy with subsequent tapering may be an effective treatment in patients with COVID-19 up to the age of early 70s; however, severe complications may be seen in elderly patients.
- Open Access
- 4 May 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (6) , e00761
Ultrasonic humidifier lung as a mimic of COVID‐19
Chest computed tomography (CT) has been used to complement coronavirus disease 2019 (COVID‐19) diagnosis due to its high sensitivity. However, owing to the low specificity of CT findings, differential diagnosis is essential. The typical CT findings of COVID‐19 include ground‐glass opacifications and consolidations with predominant distribution in bilateral, peripheral, and subpleural parts of the lung. These imaging findings are non‐specific and may resemble other lung conditions, including ultrasonic humidifier lung, which is a condition that develops on inhaling aerosols generated by ultrasonic humidifiers. We present two patients with initial symptoms similar to COVID‐19. CT examination revealed centrilobular nodules and consolidations with upper lobe‐predominant distribution, although atypical for COVID‐19, but key findings for ultrasonic humidifier lung. Therefore, ultrasonic humidifier lung could be a differential diagnosis for COVID‐19 in dry environments. Characteristic CT findings and a history of ultrasonic humidifier use are critical to the final diagnosis.
- 4 May 2021
- Published by Wiley in Respirology Case Reports
- Vol. 9 (6) , e00761
Open AccessUltrasonic humidifier lung as a mimic of COVID‐19
Chest computed tomography (CT) has been used to complement coronavirus disease 2019 (COVID‐19) diagnosis due to its high sensitivity. However, owing to the low specificity of CT findings, differential diagnosis is essential. The typical CT findings of COVID‐19 include ground‐glass opacifications and consolidations with predominant distribution in bilateral, peripheral, and subpleural parts of the lung. These imaging findings are non‐specific and may resemble other lung conditions, including ultrasonic humidifier lung, which is a condition that develops on inhaling aerosols generated by ultrasonic humidifiers. We present two patients with initial symptoms similar to COVID‐19. CT examination revealed centrilobular nodules and consolidations with upper lobe‐predominant distribution, although atypical for COVID‐19, but key findings for ultrasonic humidifier lung. Therefore, ultrasonic humidifier lung could be a differential diagnosis for COVID‐19 in dry environments. Characteristic CT findings and a history of ultrasonic humidifier use are critical to the final diagnosis.
- Open Access
- 4 June 2020
- Published by Wiley in Respirology Case Reports
- Vol. 8 (6) , e00596
High‐dose, short‐term corticosteroids for ARDS caused by COVID‐19: a case series
We report a case series of seven mechanically ventilated patients with acute respiratory distress syndrome (ARDS) caused by coronavirus disease (COVID‐19) who received early treatment with high‐dose, short‐term systemic corticosteroids to prevent cytokine overproduction. Of the seven patients, four were male and median age was 69 years. They were intubated within seven days after admission when their respiratory status rapidly worsened. At that time, we administered 1000 or 500 mg/day for three days of methylprednisolone intravenously, followed by 1 mg/kg and tapered off. The median duration for the total administration of corticosteroids was 13 days. This high‐dose, short‐term corticosteroid therapy enabled extubation of the patients within seven days. Many questions on the clinical management of COVID‐19 remain unanswered, and data on corticosteroid therapy as a choice of treatment are mixed. We present the clinical course of our cases, review the previous evidence, and discuss management.
- 4 June 2020
- Published by Wiley in Respirology Case Reports
- Vol. 8 (6) , e00596
Open AccessHigh‐dose, short‐term corticosteroids for ARDS caused by COVID‐19: a case series
We report a case series of seven mechanically ventilated patients with acute respiratory distress syndrome (ARDS) caused by coronavirus disease (COVID‐19) who received early treatment with high‐dose, short‐term systemic corticosteroids to prevent cytokine overproduction. Of the seven patients, four were male and median age was 69 years. They were intubated within seven days after admission when their respiratory status rapidly worsened. At that time, we administered 1000 or 500 mg/day for three days of methylprednisolone intravenously, followed by 1 mg/kg and tapered off. The median duration for the total administration of corticosteroids was 13 days. This high‐dose, short‐term corticosteroid therapy enabled extubation of the patients within seven days. Many questions on the clinical management of COVID‐19 remain unanswered, and data on corticosteroid therapy as a choice of treatment are mixed. We present the clinical course of our cases, review the previous evidence, and discuss management.
- Open Access
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A6833
Long-Term Follow-Up of Interstitial Pneumonia Associated with Systemic Sclerosis
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A6833
Open AccessLong-Term Follow-Up of Interstitial Pneumonia Associated with Systemic Sclerosis